International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

Naveen Luke Pereira, Derek So, Jang Ho Bae, Ivan Chavez, Myung Ho Jeong, Sang Wook Kim, Mina Madan, John Graham, Fearghas O'Cochlain, Nicole Pauley, Ryan J. Lennon, Kent R Bailey, Ahmed Hasan, Linnea M. Baudhuin, Malcolm R. Bell, Amir Lerman, Shaun Goodman, Verghese Mathew, Michael Farkouh, Charanjit Rihal

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist. PARTICIPANTS AND METHODS: TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization. RESULTS: A total of 1327 patients completed baseline surveys of whom 28, 29, and 43% were from Korea, Canada and the USA, respectively. Most patients (77%) valued identifying pharmacogenetic variants; however, fewer Koreans (44%) as compared with Canadians (91%) and USA (89%) patients identified pharmacogenetics as being important (P<0.001). After adjusting for age, sex, and country, those who were confident in their ability to understand genetic information were significantly more likely to value identifying pharmacogenetic variants (odds ratio: 30.0; 95% confidence interval: 20.5-43.8). Only 21% of Koreans, as opposed to 86 and 77% of patients in Canada and USA, respectively, were confident in their ability to understand genetic information (P<0.001). CONCLUSION: Although genetically mediated clopidogrel resistance is more prevalent amongst Asians, Koreans undergoing PCI identified pharmacogenetic variants as less important to their healthcare, likely related to their lack of confidence in their ability to understand genetic information. To enable successful implementation of pharmacogenetic testing on a global scale, the possibility of international population differences in perceptions should be considered.

Original languageEnglish (US)
Pages (from-to)76-83
Number of pages8
JournalPharmacogenetics and genomics
Volume29
Issue number4
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Aptitude
clopidogrel
Canada
Pharmacogenetics
Korea
Random Allocation
Pharmacogenomic Testing
Surveys and Questionnaires
Therapeutics
Odds Ratio
Genotype
Clinical Trials
Confidence Intervals
Delivery of Health Care
Population
Pharmacogenomic Variants

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. / Pereira, Naveen Luke; So, Derek; Bae, Jang Ho; Chavez, Ivan; Jeong, Myung Ho; Kim, Sang Wook; Madan, Mina; Graham, John; O'Cochlain, Fearghas; Pauley, Nicole; Lennon, Ryan J.; Bailey, Kent R; Hasan, Ahmed; Baudhuin, Linnea M.; Bell, Malcolm R.; Lerman, Amir; Goodman, Shaun; Mathew, Verghese; Farkouh, Michael; Rihal, Charanjit.

In: Pharmacogenetics and genomics, Vol. 29, No. 4, 01.06.2019, p. 76-83.

Research output: Contribution to journalArticle

Pereira, NL, So, D, Bae, JH, Chavez, I, Jeong, MH, Kim, SW, Madan, M, Graham, J, O'Cochlain, F, Pauley, N, Lennon, RJ, Bailey, KR, Hasan, A, Baudhuin, LM, Bell, MR, Lerman, A, Goodman, S, Mathew, V, Farkouh, M & Rihal, C 2019, 'International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing', Pharmacogenetics and genomics, vol. 29, no. 4, pp. 76-83. https://doi.org/10.1097/FPC.0000000000000368
Pereira, Naveen Luke ; So, Derek ; Bae, Jang Ho ; Chavez, Ivan ; Jeong, Myung Ho ; Kim, Sang Wook ; Madan, Mina ; Graham, John ; O'Cochlain, Fearghas ; Pauley, Nicole ; Lennon, Ryan J. ; Bailey, Kent R ; Hasan, Ahmed ; Baudhuin, Linnea M. ; Bell, Malcolm R. ; Lerman, Amir ; Goodman, Shaun ; Mathew, Verghese ; Farkouh, Michael ; Rihal, Charanjit. / International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. In: Pharmacogenetics and genomics. 2019 ; Vol. 29, No. 4. pp. 76-83.
@article{6be04c954c684175b26fa02ab061417f,
title = "International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing",
abstract = "OBJECTIVE: To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist. PARTICIPANTS AND METHODS: TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization. RESULTS: A total of 1327 patients completed baseline surveys of whom 28, 29, and 43{\%} were from Korea, Canada and the USA, respectively. Most patients (77{\%}) valued identifying pharmacogenetic variants; however, fewer Koreans (44{\%}) as compared with Canadians (91{\%}) and USA (89{\%}) patients identified pharmacogenetics as being important (P<0.001). After adjusting for age, sex, and country, those who were confident in their ability to understand genetic information were significantly more likely to value identifying pharmacogenetic variants (odds ratio: 30.0; 95{\%} confidence interval: 20.5-43.8). Only 21{\%} of Koreans, as opposed to 86 and 77{\%} of patients in Canada and USA, respectively, were confident in their ability to understand genetic information (P<0.001). CONCLUSION: Although genetically mediated clopidogrel resistance is more prevalent amongst Asians, Koreans undergoing PCI identified pharmacogenetic variants as less important to their healthcare, likely related to their lack of confidence in their ability to understand genetic information. To enable successful implementation of pharmacogenetic testing on a global scale, the possibility of international population differences in perceptions should be considered.",
author = "Pereira, {Naveen Luke} and Derek So and Bae, {Jang Ho} and Ivan Chavez and Jeong, {Myung Ho} and Kim, {Sang Wook} and Mina Madan and John Graham and Fearghas O'Cochlain and Nicole Pauley and Lennon, {Ryan J.} and Bailey, {Kent R} and Ahmed Hasan and Baudhuin, {Linnea M.} and Bell, {Malcolm R.} and Amir Lerman and Shaun Goodman and Verghese Mathew and Michael Farkouh and Charanjit Rihal",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/FPC.0000000000000368",
language = "English (US)",
volume = "29",
pages = "76--83",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

AU - Pereira, Naveen Luke

AU - So, Derek

AU - Bae, Jang Ho

AU - Chavez, Ivan

AU - Jeong, Myung Ho

AU - Kim, Sang Wook

AU - Madan, Mina

AU - Graham, John

AU - O'Cochlain, Fearghas

AU - Pauley, Nicole

AU - Lennon, Ryan J.

AU - Bailey, Kent R

AU - Hasan, Ahmed

AU - Baudhuin, Linnea M.

AU - Bell, Malcolm R.

AU - Lerman, Amir

AU - Goodman, Shaun

AU - Mathew, Verghese

AU - Farkouh, Michael

AU - Rihal, Charanjit

PY - 2019/6/1

Y1 - 2019/6/1

N2 - OBJECTIVE: To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist. PARTICIPANTS AND METHODS: TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization. RESULTS: A total of 1327 patients completed baseline surveys of whom 28, 29, and 43% were from Korea, Canada and the USA, respectively. Most patients (77%) valued identifying pharmacogenetic variants; however, fewer Koreans (44%) as compared with Canadians (91%) and USA (89%) patients identified pharmacogenetics as being important (P<0.001). After adjusting for age, sex, and country, those who were confident in their ability to understand genetic information were significantly more likely to value identifying pharmacogenetic variants (odds ratio: 30.0; 95% confidence interval: 20.5-43.8). Only 21% of Koreans, as opposed to 86 and 77% of patients in Canada and USA, respectively, were confident in their ability to understand genetic information (P<0.001). CONCLUSION: Although genetically mediated clopidogrel resistance is more prevalent amongst Asians, Koreans undergoing PCI identified pharmacogenetic variants as less important to their healthcare, likely related to their lack of confidence in their ability to understand genetic information. To enable successful implementation of pharmacogenetic testing on a global scale, the possibility of international population differences in perceptions should be considered.

AB - OBJECTIVE: To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist. PARTICIPANTS AND METHODS: TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization. RESULTS: A total of 1327 patients completed baseline surveys of whom 28, 29, and 43% were from Korea, Canada and the USA, respectively. Most patients (77%) valued identifying pharmacogenetic variants; however, fewer Koreans (44%) as compared with Canadians (91%) and USA (89%) patients identified pharmacogenetics as being important (P<0.001). After adjusting for age, sex, and country, those who were confident in their ability to understand genetic information were significantly more likely to value identifying pharmacogenetic variants (odds ratio: 30.0; 95% confidence interval: 20.5-43.8). Only 21% of Koreans, as opposed to 86 and 77% of patients in Canada and USA, respectively, were confident in their ability to understand genetic information (P<0.001). CONCLUSION: Although genetically mediated clopidogrel resistance is more prevalent amongst Asians, Koreans undergoing PCI identified pharmacogenetic variants as less important to their healthcare, likely related to their lack of confidence in their ability to understand genetic information. To enable successful implementation of pharmacogenetic testing on a global scale, the possibility of international population differences in perceptions should be considered.

UR - http://www.scopus.com/inward/record.url?scp=85065083254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065083254&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000368

DO - 10.1097/FPC.0000000000000368

M3 - Article

VL - 29

SP - 76

EP - 83

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 4

ER -